Results 111 to 120 of about 25,234 (166)

Knowledge domain and emerging trends on the SGLT2 inhibitor dapagliflozin for heart failure: a bibliometric analysis from 2012 to 2024. [PDF]

J Cardiothorac Surg
Xiao M, Sui Y, Fu D, Gong S, Xiong N, Wu Y, Xiong W.   +6 more
europepmc   +1 more source

SGLT2 Inhibitor Might Prevent Atrial Fibrillation Related to Metabolic Syndrome via TNF-α Signaling Pathway: A Bioinformatic Study. [PDF]

J Arrhythm
Rizal A, Rohman MS, Prastya A, Fatchiyah F, Sujuti H, Rudianto A, Prayitnaningsih S.   +6 more
europepmc   +1 more source

Multiple Effects of SGLT2 Inhibitors

JMA Journal
openaire   +2 more sources

Identification of IL18/IL18R1 signaling as a predictive biomarker of SGLT2 inhibitor efficacy in type 2 diabetes. [PDF]

iScience
Teng IJ, Lee CH, Chen YC, Su SC, Lu CH, Li PF, Huang CL, Ho LJ, Lin MH, Liu HY, Kuo FC.   +10 more
europepmc   +1 more source

Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide. [PDF]

JCEM Case Rep
Louwagie EJ, Diego JN, Farooqi CS, Kamal MM.   +3 more
europepmc   +1 more source

A Novel Presentation of Euglycemic Diabetic Ketoacidosis Associated with SGLT2 Inhibitor and Weekly GLP-1 Agonist: Case Report. [PDF]

Healthcare (Basel)
Lyu YS.
europepmc   +1 more source

Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes. [PDF]

Cardiovasc Diabetol
Lyu YS, Lee H, Kim KS, Hong S, Park CY.
europepmc   +1 more source

Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis.

JAMA Surg
Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiovascular benefit of SGLT2 inhibitors

Critical Reviews in Clinical Laboratory Sciences, 2021
Patients with type 2 diabetes mellitus (T2D) are at increased risk of cardiovascular (CV) disease. Sodium glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, are a class of medications used to treat T2D by preventing the reabsorption of glucose filtered through the kidney and thereby facilitating glucose excretion in the urine.
Reza, Mohebi, James L, Januzzi
openaire   +2 more sources